Li, Ziming
Song, Zhengbo
Hong, Wei
Yang, Nong
Wang, Yongsheng
Jian, Hong
Liang, Zibin
Hu, Sheng
Peng, Min
Yu, Yan
Wang, Yan
Jiao, Zicong
Zhao, Kaijing
Song, Ke
Li, You
Shi, Wei
Lu, Shun http://orcid.org/0000-0001-8833-7262
Article History
Received: 7 February 2024
Revised: 27 May 2024
Accepted: 18 June 2024
First Online: 15 July 2024
Competing interests
: S. Lu reports research grant from AstraZeneca, Abbvie, Roche, Bristol-Myers Squibb, Hutchison Whampoa, BeiGene, Daiichi Sankyo, Bayer, FibroGen, Hansoh Pharma, Hengrui, Innovent, Zai Lab, Betta, Akesobio and Inventisbio; H. Jian reports research grant from Hansoh Pharma and Hengrui; Z. Jiao is an employee of Geneplus-Beijing; K. Zhao, K. Song, Y. Li and W. Shi are employees of Jiangsu Hengrui Pharmaceuticals. The remaining authors declare no competing interests.